Vectura Group PLC (VEC) Receives “Buy” Rating from Numis Securities Ltd
Vectura Group PLC (LON:VEC)‘s stock had its “buy” rating restated by analysts at Numis Securities Ltd in a report issued on Thursday. They currently have a GBX 205 ($2.65) price target on the stock. Numis Securities Ltd’s target price indicates a potential upside of 113.99% from the company’s current price.
Several other analysts have also recently weighed in on VEC. Peel Hunt reissued a “hold” rating and issued a GBX 160 ($2.07) price target on shares of Vectura Group PLC in a research note on Wednesday. Shore Capital reissued a “buy” rating on shares of Vectura Group PLC in a research note on Wednesday, August 16th. N+1 Singer reissued a “hold” rating on shares of Vectura Group PLC in a research note on Thursday, June 29th. Panmure Gordon reissued a “buy” rating on shares of Vectura Group PLC in a research note on Wednesday, August 30th. Finally, J P Morgan Chase & Co dropped their price target on shares of Vectura Group PLC from GBX 240 ($3.10) to GBX 210 ($2.71) and set an “overweight” rating for the company in a research note on Friday, May 12th. One research analyst has rated the stock with a sell rating, two have issued a hold rating and eight have given a buy rating to the company. The stock presently has an average rating of “Buy” and an average target price of GBX 209 ($2.70).
Shares of Vectura Group PLC (LON:VEC) traded up 6.50% during mid-day trading on Thursday, reaching GBX 95.80. 1,945,108 shares of the company’s stock traded hands. Vectura Group PLC has a 12-month low of GBX 88.90 and a 12-month high of GBX 166.97. The stock’s market capitalization is GBX 649.19 million. The company’s 50-day moving average price is GBX 110.07 and its 200-day moving average price is GBX 127.61.
Vectura Group PLC (LON:VEC) last posted its quarterly earnings results on Tuesday, September 5th. The company reported $0.04 earnings per share for the quarter, beating the consensus estimate of $0.02 by $0.02. Vectura Group PLC had a negative net margin of 48.35% and a negative return on equity of 11.44%. Analysts anticipate that Vectura Group PLC will post $4.72 earnings per share for the current year.
COPYRIGHT VIOLATION NOTICE: “Vectura Group PLC (VEC) Receives “Buy” Rating from Numis Securities Ltd” was reported by American Banking News and is the sole property of of American Banking News. If you are accessing this piece of content on another website, it was copied illegally and reposted in violation of U.S. & international copyright and trademark legislation. The original version of this piece of content can be accessed at https://www.americanbankingnews.com/2017/09/10/vectura-group-plc-vec-receives-buy-rating-from-numis-securities-ltd.html.
In other Vectura Group PLC news, insider Andrew Derodra bought 82,000 shares of Vectura Group PLC stock in a transaction on Thursday, September 7th. The shares were bought at an average cost of GBX 90 ($1.16) per share, for a total transaction of £73,800 ($95,311.89).
About Vectura Group PLC
Vectura Group plc is engaged in research, development and commercialization of therapeutic products and drug delivery systems for human use. The Company’s products include Ultibro Breezhaler (European Union (EU) and Rest of World (RoW)) – LABA-LAMA; Seebri Breezhaler (EU and RoW) – LAMA; AirFluSal Forspiro (EU and RoW) – ICS-LABA; ADVATE (Global) – Antihaemophilic Factor (Recombinant); Adept (Global) – Icodextrin; Anoro Ellipta (Global) – LAMA-LABA; Relvar Ellipta/Breo Ellipta (Global) – ICS-LABA, and Incruse Ellipta (Global) – LAMA.
Receive News & Ratings for Vectura Group PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vectura Group PLC and related companies with MarketBeat.com's FREE daily email newsletter.